Amgen and Allergan receive positive CHMP opinion for ABP 980 (biosimilar Herceptin®)
Amgen announced the CHMP of the EMA has adopted a positive opinion to include a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels. March 23, 2018